This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PSA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.
Prostate cancer patients treated with radical prostatectomy
1. Received neoadjuvant endocrine/chemotherapy before surgery;
2. Urine leakage after surgery (positive creatinine test of drainage fluid).
The study will include male patients diagnosed with prostate cancer who need radical prostatectomy. Participants must have a preoperative diagnosis confirmed by biopsy and imaging studies. Eligible patients will have an abdominal drainage system in place post-surgery for fluid collection.
Cohort
Prospective
Not listed
PSA Levels in Drainage Fluid
Postoperative Prostate-Specific Antigen (PSA) Levels in The Peritoneal Drainage Fluid
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
